A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ED / exposure days

[Related PubMed/MEDLINE]
Total Number of Papers: 18
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ED  (>> Co-occurring Abbreviation)
Long Form:   exposure days
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. PUPs, SHB
2018 [Source Analysis and Environmental Health Risk Assessment of VOCs in Furniture Manufacturing]. EF, ET
2017 Evaluation of the safety of conventional lighting replacement by artificial daylight. ---
2017 Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. rFVIII
2017 [Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab]. ITI, PCC
2016 Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia. FVIII, HD ITI, HR, HRs, ITIs, pdFVIII, PUPs, rFVIII
2015 Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening. FLI, HTI, LTI
2014 Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. FVIII, ID, OR, PUPs
2014 Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. ---
10  2012 Risk of inhibitor development in mild haemophilia A increases with age. FVIII
11  2011 Clinical experience with Optivate, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A. FVIII, PUP, vWF
12  2011 Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate: interim report from an ongoing prospective clinical study. FVIII, HA, IVR, PUPs
13  2009 Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports. FVIII, ITI, PUPs
14  2007 Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. ReFacto
15  2006 Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections. BI, CI, FVIII
16  2003 Epidemiology of inhibitors and current treatment strategies. ITI, PUP, vWF
17  2002 Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. BU, FVIII, pd, PUPs, rFVIII
18  1999 Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. BU, FVIII, rFVIII